Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model.

Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT.

Oncogene. 2018 May;37(20):2746-2756. doi: 10.1038/s41388-018-0158-7. Epub 2018 Mar 5.

PMID:
29503447
2.

MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.

Alam M, Ahmad R, Rajabi H, Kufe D.

Mol Cancer Res. 2015 Mar;13(3):449-60. doi: 10.1158/1541-7786.MCR-14-0363. Epub 2014 Nov 3.

3.

CD44 promotes Kras-dependent lung adenocarcinoma.

Zhao P, Damerow MS, Stern P, Liu AH, Sweet-Cordero A, Siziopikou K, Neilson JR, Sharp PA, Cheng C.

Oncogene. 2013 Oct 24;32(43):5186-90. doi: 10.1038/onc.2012.542. Epub 2012 Dec 3.

4.

MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.

Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D.

Oncotarget. 2014 Oct 15;5(19):8893-905.

5.

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.

Sato H, Shien K, Tomida S, Okayasu K, Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.

Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.

6.

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.

PLoS One. 2013 Nov 15;8(11):e80885. doi: 10.1371/journal.pone.0080885. eCollection 2013.

7.

PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.

Green S, Trejo CL, McMahon M.

Cancer Res. 2015 Dec 15;75(24):5378-91. doi: 10.1158/0008-5472.CAN-15-1249. Epub 2015 Nov 13.

8.

MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.

Lu C, Shan Z, Hong J, Yang L.

Int J Oncol. 2017 Jul;51(1):235-244. doi: 10.3892/ijo.2017.3999. Epub 2017 May 16.

PMID:
28534966
9.

A mathematical model for microRNA in lung cancer.

Kang HW, Crawford M, Fabbri M, Nuovo G, Garofalo M, Nana-Sinkam SP, Friedman A.

PLoS One. 2013;8(1):e53663. doi: 10.1371/journal.pone.0053663. Epub 2013 Jan 24.

10.

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer.

Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D, Sullivan JP, Dospoy PD, Augustyn A, Hight SK, Sato M, Girard L, Behrens C, Wistuba II, Gazdar AF, Hayward NK, Minna JD.

J Clin Invest. 2016 Sep 1;126(9):3219-35. doi: 10.1172/JCI76725. Epub 2016 Aug 8.

11.

Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.

Lu W, Zhang H, Niu Y, Wu Y, Sun W, Li H, Kong J, Ding K, Shen HM, Wu H, Xia D, Wu Y.

Mol Cancer. 2017 Jul 11;16(1):118. doi: 10.1186/s12943-017-0685-9. Erratum in: Mol Cancer. 2017 Aug 29;16(1):144.

12.

miR-26a suppresses EMT by disrupting the Lin28B/let-7d axis: potential cross-talks among miRNAs in IPF.

Liang H, Liu S, Chen Y, Bai X, Liu L, Dong Y, Hu M, Su X, Chen Y, Huangfu L, Li X, Gu Y, Shan H.

J Mol Med (Berl). 2016 Jun;94(6):655-65. doi: 10.1007/s00109-016-1381-8. Epub 2016 Jan 20.

PMID:
26787543
13.

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.

Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B.

Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162.

15.

Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer.

Kelly-Spratt KS, Philipp-Staheli J, Gurley KE, Hoon-Kim K, Knoblaugh S, Kemp CJ.

Oncogene. 2009 Oct 15;28(41):3652-62. doi: 10.1038/onc.2009.226. Epub 2009 Aug 3.

16.

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer.

Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF.

Mol Cancer Res. 2017 Dec;15(12):1764-1776. doi: 10.1158/1541-7786.MCR-17-0298. Epub 2017 Aug 29.

17.

miR-203 enhances let-7 biogenesis by targeting LIN28B to suppress tumor growth in lung cancer.

Zhou Y, Liang H, Liao Z, Wang Y, Hu X, Chen X, Xu L, Hu Z.

Sci Rep. 2017 Feb 20;7:42680. doi: 10.1038/srep42680.

18.

miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Zhou Y, Dang J, Chang KY, Yau E, Aza-Blanc P, Moscat J, Rana TM.

Cancer Res. 2016 Oct 1;76(19):5777-5787.

19.

MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene.

Li Y, Zhang H, Li Y, Zhao C, Fan Y, Liu J, Li X, Liu H, Chen J.

Mol Carcinog. 2018 Jan;57(1):125-136. doi: 10.1002/mc.22741. Epub 2017 Oct 16.

PMID:
28940757
20.

Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis.

Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW.

PLoS Genet. 2012;8(5):e1002650. doi: 10.1371/journal.pgen.1002650. Epub 2012 May 24.

Supplemental Content

Support Center